IMUNON, Inc. announces successful compliance with Nasdaq's minimum bid price requirement for continued listing.
Investors assured of efficient liquidity with uninterrupted trading on The Nasdaq Capital Market.
Company reflects confidence in clinical pipeline post successful Phase 2 trial results for IMNN-001.
IMUNON actively advancing milestones in Phase 3 trial and TheraPlas® technology platform.
Regained Compliance
Confirmed compliance with Nasdaq minimum bid price requirement.
Stock Dividend
Issued 15% stock dividend to shareholders as a sign of confidence.
Positive Momentum
Building on successful Phase 2 trial results for IMNN-001 in treating ovarian cancer.
TheraPlas® Technology
Innovative approach using non-viral DNA technology for immunological therapies.
- IMUNON ensures continued trading benefits with Nasdaq compliance.
- Stock dividend reflects company's confidence and commitment to investors.
- Phase 2 trial success propels positive momentum for IMNN-001 and ongoing Phase 3 trial.
- Advancements in TheraPlas® technology platform signify innovation in immunotherapy approaches.
IMUNON's regained compliance with Nasdaq listing requirements and positive trial results mark significant progress in its biotechnology offerings, including innovative immunotherapy solutions.